Best Treatment Selection in Clear-Cell RCC

October 4, 2024

By Moshe Ornstein, MD, MA
Karine Tawagi, MD

Opinion

Video

Medical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.

EP: 1.Overview of RCC: Clear-Cell and Non–clear Cell

EP: 2.Challenges in Treating RCC From Community and Academic Settings

EP: 3.Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates

EP: 4.KEYNOTE-B61: Clinical Implications of Efficacy and Safety Data in Practice

EP: 5.nccRCC: Alternative Therapies

EP: 6.Role of Histology and Data in Selecting Optimal Therapy in nccRCC

EP: 7.AE Management of IO/TKI and Future of nccRCC

EP: 8.KEYNOTE-564: Pembrolizumab as Adjuvant Therapy

EP: 9.NCCN Guideline Updates in Clear-Cell RCC

Now Viewing

EP: 10.Best Treatment Selection in Clear-Cell RCC

Video content above is prompted by the following:

Describe your thought process when deciding between an IO-IO regimen and IO-TKI regimen for 1L.(56:23- END)

What factors might you consider (safety profile, best response, etc) in community vs academic settings?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!